SCHEMBL7364597

SCHEMBL7364597

CCP(=O)(Cl)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
GAA P10253 2/20 0.48
TSHR P16473 2/20 0.48
PKM P14618 1/20 0.48
MAPT P10636 3/20 0.46
ACHE P22303 1/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 1/20 0.44
CFTR P13569 1/20 0.43
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA5A P35218 1/20 0.42
ALPG P10696 1/20 0.41
ALOX12 P18054 1/20 0.41
NPY1R P25929 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6572723 0.78 CFTR (0.44) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL18860622 0.77 ALDH1A1 (0.35) ALDH1A1MEN1KMT2AGAASMN1; SMN2
SCHEMBL27877604 0.76 CFTR (0.43) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL18860646 0.76 L3MBTL1 (0.40) ALDH1A1MEN1KMT2AGAAMAPT
SCHEMBL9796121 0.76 NPSR1 (0.52) ALDH1A1MEN1KMT2AGAAPKM
SCHEMBL9463262 0.76 NPSR1 (0.52) ALDH1A1MEN1KMT2AGAAPKM
SCHEMBL27262190 0.75 MEN1 (0.42) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL778908 0.75 ALDH1A1 (0.52) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL777736 0.75 ALDH1A1 (0.59) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL28270684 0.74 CFTR (0.41) ALDH1A1MEN1KMT2AGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113801318-A Bishydroxy low molecular weight polyphenylene ether alkyl phosphate, thermosetting resin composition containing the same, and use thereof 兰州瑞朴科技有限公司 2021-12-17 CN disclosed
EP-2537839-B1 B-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING B-DIHYDROFURAN DERIVING COMPOUND OR B-TETRAHYDROFURAN DERIVING COMPOUND, B -GLYCOSIDE COMPOUND, METHOD FOR PRODUCING B-GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF NISSAN CHEMICAL IND LTD (JP) 2016-12-14 EP disclosed
US-9212174-B2 Certain β-dihydrofuran derivatives NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-12-15 US disclosed
CN-102741237-B Method for producing beta-dihydrofuran deriving compound NISSAN CHEMICAL IND LTD 2015-04-29 CN disclosed
EP-2537839-A1 B-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING B-DIHYDROFURAN DERIVING COMPOUND OR B-TETRAHYDROFURAN DERIVING COMPOUND, B -GLYCOSIDE COMPOUND, METHOD FOR PRODUCING B-GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF Nissan Chemical Industries, Ltd. (JP) 2012-12-26 EP disclosed
US-20120322995-A1 beta-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING beta-DIHYDROFURAN DERIVING COMPOUND OR beta-TETRAHYDROFURAN DERIVING COMPOUND, beta-GLYCOSIDE COMPOUND, METHOD FOR PRODUCING beta GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-12-20 US disclosed
CN-102741237-A Beta-dihydrofuran deriving compound, method for producing beta-dihydrofuran deriving compound or beta-tetrahydrofuran deriving compound, beta-glycoside compound, method for producing beta-glycoside compound, and method for producing 4'-ethynyl d4t and analogue comp NISSAN CHEMICAL IND LTD 2012-10-17 CN disclosed
US-20100004158-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME CORP. 2010-01-07 US disclosed
EP-0925303-B1 PHOSPHINIC ACID AMIDES AS MATRIX METALLOPROTEASE INHIBITORS PROCTER & GAMBLE (US) 2002-10-23 EP disclosed
EP-0925303-A1 PHOSPHINIC ACID AMIDES AS MATRIX METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1999-06-30 EP disclosed
US-5830915-A ORAL DISEASES; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY (US) 1998-11-03 US disclosed
WO-1998008853-A9 PHOSPHINIC ACID AMIDES AS MATRIX METALLOPROTEASE INHIBITORS 1998-08-06 WO disclosed
WO-1998008853-A1 PHOSPHINIC ACID AMIDES AS MATRIX METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1998-03-05 WO disclosed
EP-0122587-B1 PROCESS FOR PREPARING ORGANIC CHLOROPHOSPHANES HOECHST AKTIENGESELLSCHAFT (DE) 1988-04-20 EP disclosed
EP-0144743-B1 PROCESS FOR THE PREPARATION OF ORGANIC CHLOROPHOSPHANES HOECHST AKTIENGESELLSCHAFT (DE) 1988-01-07 EP disclosed
US-4656293-A Process for preparing organic chlorophosphanes HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-07 US disclosed
US-4632995-A Process for the preparation of phenyl- and thienyl-chlorophosphane derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1986-12-30 US disclosed
EP-0144743-A1 Process for the preparation of organic chlorophosphanes HOECHST AKTIENGESELLSCHAFT (DE) 1985-06-19 EP disclosed
EP-0122587-A2 Process for preparing organic chlorophosphanes HOECHST AKTIENGESELLSCHAFT (DE) 1984-10-24 EP disclosed
US-4242479-A CATALYST OF ALUMINUM TRIHALIDE, ORGANOSILOXANE COMPOUND OR ETHER, MAGNESIUM ALCOHOLATE, TITANIUM-HALOGEN AND ORGANOALUMINUM COMPOUNDS SHOWA YUKA KABUSHIKI KAISHA (JP) 1980-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004158-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE GCGR, GLP1R, GPR119 ALDH1A1 4524/4885MEN1 1591/4885KMT2A 4415/4885
US-20120322995-A1 beta-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING beta-DIHYDROFURAN DERIVING COMPOUND OR beta-TETRAHYDROFURAN DERIVING COMPOUND, beta-GLYCOSIDE COMPOUND, METHOD FOR PRODUCING beta GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF DHPS, B4GALT1, STT3A ALDH1A1 495/4885MEN1 1328/4885KMT2A 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.